

Milan J Sonneveld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6823291/publications.pdf>

Version: 2024-02-01

61
papers

2,228
citations

361045

20
h-index

223531

46
g-index

62
all docs

62
docs citations

62
times ranked

1938
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. <i>Hepatology</i> , 2010, 52, 1251-1257.	3.6	259
2	Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. <i>Hepatology</i> , 2013, 58, 872-880.	3.6	201
3	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. <i>Gut</i> , 2015, 64, 1289-1295.	6.1	178
4	Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2012, 142, 513-520.e1.	0.6	171
5	Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. <i>Gut</i> , 2013, 62, 760-765.	6.1	159
6	Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). <i>Hepatology</i> , 2015, 61, 1512-1522.	3.6	145
7	Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. <i>Journal of Hepatology</i> , 2011, 54, 449-454.	1.8	134
8	Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2012, 56, 67-75.	3.6	75
9	Hepatitis B Surface Antigen Declines and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV. <i>Journal of Infectious Diseases</i> , 2012, 206, 974-980.	1.9	68
10	Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?. <i>Gut</i> , 2012, 61, 641-645.	6.1	65
11	Durable Hepatitis B Surface Antigen Decline in Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon- α 2B: Relation to Response and HBV Genotype. <i>Antiviral Therapy</i> , 2012, 17, 9-17.	0.6	63
12	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. <i>Journal of Hepatology</i> , 2022, 76, 1042-1050.	1.8	54
13	Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100350.	2.6	52
14	A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. <i>Journal of Clinical Virology</i> , 2011, 51, 175-178.	1.6	49
15	Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 538-544.	3.7	49
16	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e784-e793.	2.4	49
17	Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. <i>Journal of Hepatology</i> , 2013, 58, 898-903.	1.8	46
18	Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?. <i>Liver International</i> , 2011, 31, 78-84.	1.9	38

#	ARTICLE	IF	CITATIONS
19	Close Monitoring of Hepatitis B Surface Antigen Levels Helps Classify Flares During Peginterferon Therapy and Predicts Treatment Response. <i>Clinical Infectious Diseases</i> , 2013, 56, 100-105.	2.9	34
20	Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. <i>Current Hepatitis Reports</i> , 2010, 9, 91-98.	0.3	26
21	Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1399-1406.	1.9	25
22	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1969-1979.	2.9	21
23	Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab. <i>ACG Case Reports Journal</i> , 2019, 6, e00243.	0.2	21
24	Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 314-320.	1.9	19
25	Relationship between hepatitis B core-related antigen levels and sustained <sc>HB</sc>eAg seroconversion in patients treated with nucleos(t)ide analogues. <i>Journal of Viral Hepatitis</i> , 2019, 26, 828-834.	1.0	18
26	Cerebral perfusion pressure in women with preeclampsia is elevated even after treatment of elevated blood pressure. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2014, 93, 508-511.	1.3	17
27	Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants. <i>Antiviral Research</i> , 2013, 97, 312-317.	1.9	16
28	Pegylated Interferon Results in Higher Serological, but Not Virological, Response Rates When Compared to Continuous Entecavir. <i>Antiviral Therapy</i> , 2012, 17, 1605-1608.	0.6	15
29	ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection. <i>PLoS ONE</i> , 2015, 10, e0139317.	1.1	15
30	Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1933-1940.e1.	2.4	14
31	Decrease in viral hepatitis diagnoses during the COVID-19 pandemic in the Netherlands. <i>Journal of Hepatology</i> , 2022, 77, 896-897.	1.8	12
32	Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease – implications for the clinical utility of the EASL NIT guideline. <i>Journal of Hepatology</i> , 2022, 76, 245-246.	1.8	12
33	Studies of <i>IL28B</i> genotype and response to peginterferon in chronic hepatitis B should be stratified by HBV genotype. <i>Hepatology</i> , 2013, 57, 1283-1283.	3.6	11
34	Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 1967-1973.	1.9	11
35	Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance – suggesting a valuable endpoint for early development HBV trials. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1563-1569.	1.0	11
36	The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030. <i>Journal of Clinical Medicine</i> , 2021, 10, 4562.	1.0	9

#	ARTICLE	IF	CITATIONS
37	Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2022, 227, 113-122.	1.9	8
38	Hepatitis B core-related antigen levels predict recurrence-free survival in patients with HBV-associated early-stage hepatocellular carcinoma: results from a Dutch long-term follow-up study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 205-208.	1.0	7
39	Posttreatment Hepatitis B Surface Antigen Seroreversion: The Bane of Combination Therapy in Chronic Hepatitis B?. <i>Gastroenterology</i> , 2016, 150, 1254-1255.	0.6	6
40	Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1729-1737.	1.0	6
41	Hepatitis B Core-Related Antigen Levels Predict Pegylated Interferon- α Therapy Response in HBeAg-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2020, 25, 217-222.	0.6	6
42	Hepatitis B virus treatment: Which patients should be treated with interferon?. <i>Clinical Liver Disease</i> , 2013, 2, 18-20.	1.0	5
43	Core inhibitor therapy for chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 99-100.	3.7	5
44	External Validation of the RETREAT Score for Prediction of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <i>Cancers</i> , 2022, 14, 630.	1.7	5
45	Nucleic Acid Polymer Therapy for Hepatitis B Virus: Strong Hepatitis B Surface Antigen Decline But Many Unanswered Questions. <i>Gastroenterology</i> , 2021, 160, 966-967.	0.6	4
46	Effect of the COVID-19 pandemic on procedure volumes in gastroenterology in the Netherlands. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 595-598.	3.7	4
47	Editorial: rapid disease progression in hepatitis delta—can we turn the tide?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 172-173.	1.9	2
48	Letter to the Editor: Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels Author reply. <i>Journal of Hepatology</i> , 2022, , .	1.8	2
49	Presence of anti-interferon antibodies is not associated with non-response to peginterferon treatment in chronic hepatitis B. <i>Antiviral Therapy</i> , 2013, 19, 423-427.	0.6	1
50	A Randomized Trial of Interrupted Clopidogrel in Patients Undergoing Polypectomy: More Questions Than Answers?. <i>Gastroenterology</i> , 2019, 157, 580-581.	0.6	1
51	Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page?. <i>Journal of Hepatology</i> , 2020, 73, 728-729.	1.8	1
52	Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?. <i>European Journal of Internal Medicine</i> , 2021, 89, 27-29.	1.0	1
53	Letter: rates and determinants of significant liver inflammation in chronic hepatitis B virus-infected patients with low ALT levels in the absence of significant fibrosis—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 215-216.	1.9	1
54	Editorial: stratifying risk of adverse outcomes in cirrhosis: the Hepquant SHUNT test. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 939-940.	1.9	1

#	ARTICLE	IF	CITATIONS
55	Response-guided Peginterferon Therapy for HBeAg-positive and HBeAg-negative Chronic Hepatitis B using Hepatitis B Surface Antigen Levels: A Review. <i>Current Hepatology Reports</i> , 2014, 13, 250-255.	0.4	0
56	FRI-163-Reduced liver-related complications after 13 years of follow-up of interferon-alpha treatment for HBeAg-positive chronic hepatitis B: The ELITE-B study. <i>Journal of Hepatology</i> , 2019, 70, e460.	1.8	0
57	FRI-206-Relationship between hepatitis B core related antigen levels and sustained HBeAg seroconversion in patients treated with nucleos (t)ide analogues. <i>Journal of Hepatology</i> , 2019, 70, e484.	1.8	0
58	Management of Patients With Chronic Hepatitis B (Hepadnaviridae) and Chronic Hepatitis D Infection (Deltavirus). , 2021, , 217-226.		0
59	Treatment of Hepatitis B. , 2018, , 485-500.e5.		0
60	Prevalence of hepatitis D virus coâ€infection in Austria â€“ Finding the needle in the haystack. <i>United European Gastroenterology Journal</i> , 2021, 9, 1105-1106.	1.6	0
61	Editorial: HBV cureâ€”the quest for biomarkers to predict offâ€treatment sustained response. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 555-556.	1.9	0